NEW YORK (GenomeWeb News) - ExonHit Therapeutics has granted Merck a license to its RNA splicing microarray patent, ExonHit said yesterday.
The non-exclusive license gives rights to the patent -- US No. 6,881,571, titled “Qualitative Differential Screening” -- for research use only. The patent has claims directed to microarrays optimized to monitor RNA splicing events, the company said.
ExonHit does not expect to receive more than $150,000 in revenues per year under this agreement.
Additional details were not disclosed.